Studies Highlight Newly Approved and Novel Multiple Myeloma Treatments | Page 2
Published Online: August 23, 2013
Barbara L. Jones
The most common treatment-emergent grade ≥3 adverse events were lymphopenia (19%), neutropenia (18%), thrombocytopenia (16%), and anemia (14%). In general, grade 3/4 adverse events that were emergent after 18 months were consistent with those reported during the initial 18 months.